Analyst Research Report Snapshot

Title:

ACTIVE BIOTECH - MUTED APPLAUSE

Price:

$10.00

Provider:

Edison Investment Research

Date:

03 Aug 2011

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ACTI.ST

Available for Immediate Download
Summary:

The failure of the BRAVO study to deliver a knock-out result may have sealed laquinimod’s fate as an also-ran in the epic battle of MS agents. This study missed on annualised relapse rate, its primary endpoint, although it did hit the all-important p<0.05 figure after certain adjustments and for secondary endpoints. Laquinimod could struggle as a monotherapy in the highly competitive MS market and may find itself positioned as a later-stage adjunctive therapy. Active’s stock fell by c 60%.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.